Company Overview and News


Add MELA
to your dashboard

Headline News

STRATA Skin Sciences' (SSKN) CEO Frank McCaney on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day and welcome to the STRATA Skin Sciences’ Third Quarter 2017 Earnings Conference Call. Today’s conference is being recorded. (4-0)

BRIEF-Leviticus Partners reports 9.69 pct passive stake in Strata Skin Sciences

2017-11-02 reuters
* Says reports 9.69 pct passive stake in Strata Skin Sciences Inc as of Oct 24, 2017 - SEC filing‍​ Source text - (bit.ly/2h6vUO5) (4-1)

SSKN / Strata Skin Sciences, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-02 fintel.io
Strata Skin Sciences, Inc. (NASDAQ:SSKN) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 836,595 shares. Largest shareholders include Leviticus Partners L P, Sabby Management, Llc, Bridgeway Capital Management Inc, Broadfin Capital, LLC, and BlackRock Inc.. (36-2)

STRATA Skin Sciences'(SSKN) CEO Frank McCaney on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Good day and welcome to the STRATA Skin Sciences Second Quarter 2017 Earnings Conference Call. Today's conference is being recorded.

STRATA Skin Sciences' (SSKN) CEO Frank McCaney on Q1 2017 Results - Earnings Call Transcript

2017-05-11 seekingalpha
Good day and welcome to the STRATA Skin Sciences First Quarter 2017 Earnings Conference Call. Today's conference is being recorded. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session and instructions on how to queue will be provided at that time.

Trump to Nominate Gottlieb for FDA Commissioner

2017-03-13 genengnews
Scott Gottlieb, M.D., a former FDA deputy commissioner during the administration of George W. Bush, has been named by President Donald Trump as his nominee to run the agency.

Trump’s F.D.A. Pick Could Undo Decades of Drug Safeguards - The New York Times

2017-02-05 nytimes
President Trump’s vow to overhaul the Food and Drug Administration could bring major changes in policy, including steps to accelerate the process of approving new prescription drugs, setting up a clash with critics who say his push for deregulation might put consumers at risk.

Soligenix Taps a New CFO

2016-06-20 biospace
PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Karen Krumeich, as its Senior Vice President and Chief Financial Officer. Ms. Krumeich has over 25 years of diverse experience in the financial and strategic management of emerging growth life science companies.

Soligenix Appoints Karen Krumeich, as Chief Financial Officer

2016-06-20 prnewswire
PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Karen Krumeich, as its Senior Vice President and Chief Financial Officer.  Ms. Krumeich has over 25 years of diverse experience in the financial and strategic management of emerging growth life science companies.

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

2016-04-07 prnewswire
MISSISSAUGA, ON, April 7, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.

Premarket Biotech Digest: Celldex's Catalyst, Shire-Baxalta Deal, PSivida Surges

2015-12-24 seekingalpha
Celldex is set up nicely for a bounce-back in 2016.Shire and Baxalta are close to completing a deal says Reuters.PSivida surges on positive data from Phase III trial.

MELA Sciences, Inc. Earnings Q3, 2015

2015-12-01 capitalcube
Click here to see latest analysisMELA Sciences, Inc. reports financial results for the quarter ended September 30, 2015.We analyze the earnings along side the following peers of MELA Sciences, Inc. – Accuray Incorporated, Perseon Corporation, Bovie Medical Corporation, Varian Medical Systems, Inc., Danaher Corporation, PhotoMedex, Inc., General Electric Company, IsoRay, Inc. and iCAD, Inc. (ARAY-US, …

4 Small Caps Likely to Rebound?

2015-11-29 seekingalpha
by David StermanIt always pays to scroll through stocks that have taken a recent pounding, Most of the time, they've deserved to take a hit. But sometimes, investors simply over-react to seemingly bad

CUSIP: 55277R100